

ICH HARMONISED TRIPARTITE GUIDELINE

**SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA
FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS:
CHEMICAL SUBSTANCES
Q6A**

Current *Step 4* version
dated 6 October 1999

This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.

Q6A
Document History

| First Codification | History | Date | New Codification November 2005 |
|--------------------|---|--------------------|--|
| Q6A | Approval by the Steering Committee under <i>Step 2</i> and release for public consultation. | 18 July 1997 | Q6A |

Current *Step 4* version

| | | | |
|-----|--|----------------------|-----|
| Q6A | Approval by the Steering Committee under <i>Step 4</i> and recommendation for adoption to the three ICH regulatory bodies. | 6 October 1999 | Q6A |
|-----|--|----------------------|-----|

**SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA
FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS:
CHEMICAL SUBSTANCES**

ICH Harmonised Tripartite Guideline

Having reached *Step 4* of the ICH Process at the ICH Steering Committee meeting
on 6 October 1999, this guideline is recommended for
adoption to the three regulatory parties to ICH

TABLE OF CONTENTS

| | |
|--|----------|
| 1. INTRODUCTION..... | 1 |
| 1.1 Objective of the Guideline | 1 |
| 1.2 Background | 1 |
| 1.3 Scope of the Guideline | 1 |
| | |
| 2. GENERAL CONCEPTS..... | 2 |
| 2.1 Periodic or Skip Testing | 2 |
| 2.2 Release vs. Shelf-life Acceptance Criteria..... | 2 |
| 2.3 In-process Tests | 3 |
| 2.4 Design and Development Considerations | 3 |
| 2.5 Limited Data Available at Filing..... | 3 |
| 2.6 Parametric Release..... | 4 |
| 2.7 Alternative Procedures..... | 4 |
| 2.8 Pharmacopoeial Tests and Acceptance Criteria | 4 |
| 2.9 Evolving Technologies | 5 |
| 2.10 Impact of Drug Substance on Drug Product Specifications | 5 |
| 2.11 Reference Standard | 5 |
| | |
| 3. GUIDELINES..... | 5 |
| 3.1 Specifications: Definition and Justification | 5 |
| 3.1.1 Definition of Specifications..... | 5 |
| 3.1.2 Justification of Specifications..... | 6 |

| | | |
|-------|----------------------------------|-----------|
| 3.2 | Universal Tests / Criteria | 6 |
| 3.2.1 | New Drug Substances | 6 |
| 3.2.2 | New Drug Products | 7 |
| 3.3 | Specific Tests / Criteria | 8 |
| 3.3.1 | New Drug Substances | 8 |
| 3.3.2 | New Drug Products | 10 |
| | | |
| 4. | GLOSSARY..... | 18 |
| | | |
| 5. | REFERENCES..... | 20 |
| | | |
| 6. | ATTACHMENTS | 20 |

SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES

1. INTRODUCTION

1.1 Objective of the Guideline

This guideline is intended to assist to the extent possible, in the establishment of a single set of global specifications for new drug substances and new drug products. It provides guidance on the setting and justification of acceptance criteria and the selection of test procedures for new drug substances of synthetic chemical origin, and new drug products produced from them, which have not been registered previously in the United States, the European Union, or Japan.

1.2 Background

A specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. It establishes the set of criteria to which a drug substance or drug product should conform to be considered acceptable for its intended use. "Conformance to specifications" means that the drug substance and / or drug product, when tested according to the listed analytical procedures, will meet the listed acceptance criteria. Specifications are critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval.

Specifications are one part of a total control strategy for the drug substance and drug product designed to ensure product quality and consistency. Other parts of this strategy include thorough product characterization during development, upon which specifications are based, and adherence to Good Manufacturing Practices; e.g., suitable facilities, a validated manufacturing process, validated test procedure, raw material testing, in-process testing, stability testing, etc.

Specifications are chosen to confirm the quality of the drug substance and drug product rather than to establish full characterization, and should focus on those characteristics found to be useful in ensuring the safety and efficacy of the drug substance and drug product.

1.3 Scope of the Guideline

The quality of drug substances and drug products is determined by their design, development, in-process controls, GMP controls, and process validation, and by specifications applied to them throughout development and manufacture. This guideline addresses specifications, i.e., those tests, procedures, and acceptance criteria which play a major role in assuring the quality of the new drug substance and new drug product at release and during shelf life. Specifications are an important component of quality assurance, but are not its only component. All of the considerations listed above are necessary to ensure consistent production of drug substances and drug products of high quality.

This guideline addresses only the marketing approval of new drug products (including combination products) and, where applicable, new drug substances; it does not address drug substances or drug products during the clinical research stages of drug development. This guideline may be applicable to synthetic and semi-synthetic antibiotics and synthetic peptides of low molecular weight; however, it is not sufficient

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.